Analyzing Acceleron Pharma (XLRN) & The Competition
Acceleron Pharma (NASDAQ: XLRN) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Acceleron Pharma to similar businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.
This is a breakdown of recent recommendations and price targets for Acceleron Pharma and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Acceleron Pharma Competitors||767||3061||11246||227||2.71|
Acceleron Pharma currently has a consensus target price of $43.67, suggesting a potential upside of 11.97%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.93%. Given Acceleron Pharma’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Acceleron Pharma has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares Acceleron Pharma and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Acceleron Pharma||$13.14 million||-$96.08 million||-15.66|
|Acceleron Pharma Competitors||$263.26 million||$68.25 million||-6.41|
Acceleron Pharma’s competitors have higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Acceleron Pharma has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Acceleron Pharma’s competitors have a beta of 6.57, meaning that their average stock price is 557% more volatile than the S&P 500.
Institutional and Insider Ownership
77.5% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 3.9% of Acceleron Pharma shares are owned by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Acceleron Pharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Acceleron Pharma Competitors||-5,449.71%||-442.49%||-42.04%|
Acceleron Pharma competitors beat Acceleron Pharma on 8 of the 12 factors compared.
About Acceleron Pharma
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.